RenovoRx, Inc. highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah. Clinical data was presented by David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York. Patients with pancreatic cancer are commonly at risk of both arterial and venous thromboembolism, obstructions of an artery or blood vessel by a blood clot, and MVT can also be an incidental finding when treating this important patient population.

MVT is a blood clot impacting one or more of the major veins that drain blood from the intestine that may make certain treatments difficult. The data presentation highlighted that of the 25 patients randomized to the TAMP therapy, 6 failed to complete all 8 planned procedures due to thrombosis of the targeted arterial artery. Among those 6 patients, the prevalence of MVT on the baseline abdominal CT imaging was 100%.

TIGeR-PaC (NCT03257033) is currently enrolling unresectable LAPC patients at several sites across the US. Phase III TIGeR-PaC Clinical Trial: TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP? (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC).

RenovoRx?s first product candidate, RenovoGem?, is a novel oncology drug-delivery combination utilizing TAMP administration technology combined with the FDA-approved chemotherapy, gemcitabine. The study is comparing treatment with TAMP to the current standard of care of systemic intravenous chemotherapy.